Furamag, 50 mg capsules 30 pcs

Pharmacodynamics

Furamag is a broad-spectrum antimicrobial agent belonging to the group of nitrofurans.

Resistance to Furamag develops slowly and does not reach a high degree.

It is active against Gram-positive and Gram-negative microbes, pathogenic strains of Staphylococcus spp. and other microorganisms resistant to antibiotics.

It is effective against Gram-positive cocci (strepto-, staphylococci), Gram-negative bacilli (Escherichia coli, Salmonella, Shigella, Protea, Klebsiella, Enterobacteriaceae), protozoa (giardia). Furamag® is more active against Staphylococcus spp., E.coli, Aerobacter aerogenes, Bact. citrovorum, Proteus mirabilis, Proteus morganii compared to other nitrofurans. Furamag® shows higher activity against Enterococcus faecalis, Staphylococcus spp. no compared to other groups of antimicrobials.

Against most bacteria, the bacteriostatic concentration is 1:100,000 to 1:200,000; the bactericidal concentration is about 2 times higher. Under the influence of nitrofurans in microorganisms, the respiratory chain and the tricarboxylic acid cycle (Krebs cycle) are inhibited, and other biochemical processes in microorganisms are inhibited, resulting in destruction of their shell or cytoplasmic membrane. As a result of the action of nitrofurans, microorganisms release fewer toxins, so improvement in the general condition of the patient is possible even before a pronounced suppression of microflora growth. Nitrofurans, unlike many other antimicrobial agents, not only do not suppress the body’s immune system, but rather activate it (increase complement titer and ability of leukocytes to phagocytize microorganisms). Nitrofurans in therapeutic doses stimulate leukopoiesis.

Pharmacokinetics

Absorption occurs in the small intestine, by passive diffusion. Absorption of nitrofurans from the distal segment of the small intestine is 2 and 4 times higher than absorption from the proximal and middle segments, respectively (should be considered in simultaneous treatment of urogenital infections and GI diseases, including chronic enteritis). Nitrofurans are poorly absorbed in the colon.

Furamag being a mixture of potassium furazidine and magnesium hydroxycarbonate in 1:1 ratio has higher bioavailability than furazidine when taken orally (after taking Furamag capsule in acidic environment of the stomach the potassium furazidine does not convert into poorly soluble furazidine). In the body the drug is distributed evenly. Clinically important is high content of the active substance in lymph (delays the spread of infection along the lymphatic tract). In bile, its concentration is several times higher than in blood serum, and in liquor, several times lower than in serum. In saliva, the furazidine content is 30% of its concentration in serum. The concentration of furazidine in blood and tissues is relatively low, which is due to its rapid excretion, while the concentration in urine is significantly higher than in blood. Cmax in blood lasts from 3 to 7 or 8 hours, in the urine furazidine is detected 3-4 hours after use.

In contrast to nitrofurantoin (furadonin), the pH of the urine does not change after taking Furamag. In 4 hours after taking the drug the concentration of furazidine in urine is much higher than the concentration that is formed after taking the same dose of Furagin. Excretion through the kidneys occurs during glomerular filtration and tubular secretion (85%), partially subjected to reverse reabsorption in the tubules. At low concentrations of the drug in the urine the filtration and secretion process prevails, at high – the secretion decreases and reabsorption increases. Furazidine, being a weak acid, does not dissociate in acidic urine and undergoes intensive reabsorption, which may increase the development of systemic side effects. Furazidine excretion is increased when urine is alkaline.

It is slightly biotransformed (less than 10%). When renal excretory function decreases, the intensity of metabolism increases.

Indications

Periodontitis, Inflammation in the mouth, Urethritis, Inflammation of the female reproductive organs, Pharyngitis, Wounds, Burns, Stomatitis, Infectious diseases

Infections caused by microorganisms sensitive to furazidine:

• Urogenital infections (acute cystitis, urethritis, pyelonephritis);
• skin and soft tissue infections;
• severe infected burns;
• gynecological infections;

Prophylactically, it can be used during urological surgeries, cystoscopy, catheterization, etc.

Active ingredient

Furazidine

Composition

1 capsule contains:

the active ingredient:

Potassium furazidine 50 mg,

excipients:

Potassium carbonate;

Magnesium hydroxycarbonate;

Talc

.

How to take, the dosage

Overly, after meals, with plenty of fluids.

Adults – 50-100 mg (2-4 capsules of 25 mg or 1-2 capsules of 50 mg) 3 times a day.

In children – 25-50 mg (1-2 capsules of 25 mg) 3 times a day, but not more than 5 mg/kg/day.

The course of treatment is 7-10 days; if necessary the course is repeated in 10-15 days.

For prevention of infection during urological surgeries, cystoscopy, catheterization, etc. – For adults: 50 mg; for children: 25 mg once 30 minutes before the procedure.

If the next dose is not taken, the next dose should be taken at the usual time. Do not take a double dose to make up for a missed dose.

Interaction

Furamag should not be used simultaneously with ristomycin, chloramphenicol, sulfonamides (increased risk of suppression of hematopoiesis).
During the treatment it is advisable to refrain from drinking alcohol, as the side effects may increase.

It is not recommended to simultaneously prescribe drugs that can “acidify” the urine (including ascorbic acid, calcium chloride) with nitrofuran.

Special Instructions

To reduce the likelihood of side effects Furamag should be drunk with plenty of fluids.

In case of side effects the drug is discontinued (toxic effects are more common in patients with reduced renal excretory function).

Impact on the ability to drive a car or perform work requiring increased speed of physical and mental reactions. Not noted.

.

Contraindications

• high sensitivity to drugs of nitrofuran group;
• pregnancy;
• breastfeeding;
• severe chronic renal failure;
• children under 3 years of age (for this dosage form).

With caution: renal failure, glucose-6-phosphate dehydrogenase deficiency.

.

Side effects

Furamag is mildly toxic. Side effects typical for other nitrofurans have been rarely observed: headache, dizziness, nausea, vomiting, loss of appetite, polyneuritis, liver dysfunction, allergic reactions (skin rash, papular rash).

If during treatment with Furamag side effects not specified in this description are found, the treating physician must be informed.

Overdose

Symptoms: in case of overdose there are symptoms of neurotoxic nature, ataxia and tremor.

Treatment: in case of poisoning drink plenty of fluids. Antihistamines are used to relieve acute symptoms. Vitamins (thiamine bromide) may be prescribed to prevent neuritis.

.

Similarities

Furasol, Furagin, Urofuragin, Furagin-Actifur